MarketBeat Compares Monte Rosa Therapeutics and Arvinas, Inc. Stock Metrics
What happened
On September 20, 2026, Monte Rosa Therapeutics and Arvinas, Inc. were listed on Nasdaq and received analyst coverage from MarketBeat. MarketBeat compared the two small-cap healthcare companies, examining metrics such as institutional ownership, earnings, and valuation.
From themarketsdaily.com
Why it matters
The comparison showed that Monte Rosa Therapeutics has a lower price-to-earnings ratio than Arvinas, indicating it is currently more affordable. Monte Rosa Therapeutics also has a beta of 1.5, meaning its share price is 50% more volatile than the S&P 500.
From themarketsdaily.com
Who's involved
- Monte Rosa TherapeuticsBiotechnology company receiving published analyst recommendations.
- MarketBeatPersonal finance blog providing comparative analyst recommendations.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- MarketBeatSpeculative
Market price might be influenced by the comparative analyst recommendations published by MarketBeat.
Keep exploring
The entities involved
-
Monte Rosa Therapeutics
biotechnology company
Nothing else this week.
-
MarketBeat
American personal finance blog
Related events
- ProKidney and Cartesian Therapeutics were listed on the Nasdaq stock exchange and received ratings from MarketBeat.
- MarketBeat reports on company recommendations for Trimble, a company listed on the Nasdaq stock exchange.
- MarketBeat provided analyst recommendations for companies listed on the Nasdaq exchange.
- MarketBeat provides stock rating data for Vivos Therapeutics, which is listed on Nasdaq.
- BioHarvest Sciences Inc is listed on the Nasdaq stock exchange and is receiving analyst ratings and targets from MarketBeat.